Table 4.
Safety Profiles and Adverse Events
| Any Grade | Grades 3–4 | |||||
|---|---|---|---|---|---|---|
| Group, No. (%) | Group, No. (%) | |||||
| Adverse Event | Atezo/Bev-TACE Group (n=34) | LEN-TACE Group (n=34) | P value | Atezo/Bev-TACE Group (n=34) | LEN-TACE Group (n=34) | P value |
| Fever | 14 (41.2) | 17 (50.0) | 0.465 | 0 (0) | 0 (0) | 1.000 |
| Vomiting | 15 (44.1) | 18 (52.9) | 0.467 | 0 (0) | 0 (0) | 1.000 |
| Abdominal pain | 20 (58.8) | 17 (50.0) | 0.465 | 4 (11.8) | 3 (8.8) | 1.000 |
| Diarrhea | 7 (20.6) | 11 (32.4) | 0.272 | 0 (0) | 0 (0) | 1.000 |
| Constipation | 10 (29.4) | 13 (38.2) | 0.442 | 1 (2.9) | 0 (0) | 1.000 |
| Ascites | 3 (8.8) | 3 (8.8) | 1.000 | 0 (0) | 1 (2.9) | 1.000 |
| Thrombocytopenia | 7 (20.6) | 10 (29.4) | 0.401 | 0 (0) | 1 (2.9) | 1.000 |
| Anemia | 14 (41.2) | 11 (32.4) | 0.451 | 0 (0) | 3 (8.8) | 0.239 |
| Elevated AST | 28 (82.4) | 19 (55.9) | 0.018 | 6 (17.6) | 4 (11.8) | 0.493 |
| Elevated ALT | 21 (61.8) | 17 (50.0) | 0.329 | 6 (17.6) | 3 (8.8) | 0.476 |
| Hyperbilirubinemia | 11 (32.4) | 7 (20.6) | 0.272 | 2 (5.9) | 2 (5.9) | 1.000 |
| Hypoalbuminemia | 6 (17.6) | 4 (11.8) | 0.493 | 0 (0) | 0 (0) | 1.000 |
| Proteinuria | 1 (2.9) | 6 (17.6) | 0.046 | 0 (0) | 1 (2.9) | 1.000 |
| Hypertension | 10 (29.4) | 9 (26.5) | 0.787 | 5 (14.7) | 3 (8.8) | 0.709 |
| Hand-foot skin reaction | 2 (5.9) | 12 (35.3) | 0.003 | 0 (0) | 2 (5.9) | 0.493 |
| Gastrointestinal bleeding | 4 (11.8) | 6 (17.6) | 0.493 | 1 (2.9) | 2 (5.9) | 1.000 |
Abbreviations: AST, aspartate aminotransferase; ALT, alanine aminotransferase; TACE, transarterial chemoembolization; Atezo/Bev, Atezolizumab plus Bevacizumab; LEN, lenvatinib.